Skip to main content

Advertisement

SpringerLink
Log in

Reproductive Health in IBD Patients

  • Colon (JC Anderson, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Abstract

Purpose of review

Many patients with inflammatory bowel disease (IBD) are diagnosed in early adulthood, impacting their reproductive health. We discuss the recent data related to fertility, preconception counseling, the safety of IBD medications during pregnancy and lactation, delivery methods, and postpartum care in women with IBD. Additionally, we will review the psychosocial aspects, the effect of IBD, and its treatment on sexual function (SD) and fertility in men. We address the misconceptions around these topics and help the healthcare providers (HCPs) manage these patients appropriately.

Recent findings

HCPs play a crucial role in educating their patients about fertility, preconception care, efficacy, and safety of IBD therapies during pregnancy and breastfeeding. The pregnancy outcome improves significantly when the mother has been in remission for 3–6 months before conception.

Most IBD therapies are safe during pregnancy and lactation. Reproductive health in men with IBD is often neglected. SD and infertility must be addressed in women and men to achieve the best outcome.

Summary

Preconception counseling is essential to address reproductive issues in both women and men with IBD. During pregnancy, our main goal is to keep the mother in remission while avoiding adverse effects on the fetus. A multidisciplinary team approach is ideal to improve pregnancy outcomes through collaboration and shared decision-making.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol Elsevier. 2020;5:17–30.

  2. •• Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019;156:1508–24 Elsevier. Comprehensive American Gastroenterological Association IBD guidelines in pregnancy for HCPs managing IBD patients who are pregnant or planning pregnancy.

  3. • Park YE, Kim TO. Sexual dysfunction and fertility problems in men with inflammatory bowel disease. World J Mens Health. 2020;38:285–97 Review of current literature highlighting sexual dysfunction and infertility in men with IBD.

    Article  PubMed  Google Scholar 

  4. Selinger CP, Ghorayeb J, Madill A. What factors might drive voluntary childlessness (VC) in women with IBD? Does IBD-specific pregnancy-related knowledge matter? J Crohns Colitis. 2016;10:1151–8.

    Article  PubMed  Google Scholar 

  5. Ellul P, Zammita SC, Katsanos KH, Cesarini M, Allocca M, Danese S, et al. Perception of reproductive health in women with inflammatory bowel disease. J Crohns Colitis. 2016;10:886–91.

    Article  PubMed  Google Scholar 

  6. Huang VW, Chang H-J, Kroeker KI, Goodman KJ, Hegadoren KM, Dieleman LA, et al. Does the level of reproductive knowledge specific to inflammatory bowel disease predict childlessness among women with inflammatory bowel disease? Can J Gastroenterol Hepatol. 2015;29:95–103.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Friedman S, Nielsen J, Nøhr EA, Jølving LR, Nørgård BM. Comparison of time to pregnancy in women with and without inflammatory bowel diseases. Clin Gastroenterol Hepatol. Elsevier. 2020;18:1537–1544.e1.

  8. Cornish JA, Tan E, Teare J, Teoh TG, Rai R, Darzi AW, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum. 2007;50:1128–38.

    Article  PubMed  Google Scholar 

  9. Wikland M, Jansson I, Asztély M, Palselius I, Svaninger G, Magnusson O, et al. Gynaecological problems related to anatomical changes after conventional proctocolectomy and ileostomy. Int J Color Dis. 1990;5:49–52.

    Article  CAS  Google Scholar 

  10. • Gorgun E, Cengiz TB, Aytac E, Aiello A, da Silva G, Goldberg JM, et al. Does laparoscopic ileal pouch-anal anastomosis reduce infertility compared with open approach? Surgery. 2019;166:670–7 A large study demonstrating improved fertility rate with laparoscopic versus open IPAA surgery.

    Article  PubMed  Google Scholar 

  11. Zhao Y, Chen B, He Y, Zhang S, Qiu Y, Feng R, et al. Risk factors associated with impaired ovarian reserve in young women of reproductive age with Crohn’s disease. Intest Res. 2020;18:200–9.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril Elsevier. 2015;103:e44–50.

  13. Friedman S, Larsen PV, Fedder J, Nørgård BM. The reduced chance of a live birth in women with IBD receiving assisted reproduction is due to a failure to achieve a clinical pregnancy. Gut. 2017;66:556–8.

    Article  CAS  PubMed  Google Scholar 

  14. Nørgård BM, Larsen PV, Fedder J, Silva PS d, Larsen MD, Friedman S. Live birth and adverse birth outcomes in women with ulcerative colitis and Crohn’s disease receiving assisted reproduction: a 20-year nationwide cohort study. Gut. 2016;65:767–76 BMJ Publishing Group. A large nationwide cohort study showing reduced rates of ART success in IBD patients compared to the general population.

  15. Shin T, Okada H. Infertility in men with inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016;7:361–9.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Allocca M, Gilardi D, Fiorino G, Furfaro F, Peyrin-Biroulet L, Danese S. Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol. 2018;30:316–22.

    Article  PubMed  Google Scholar 

  17. Gutierrez JC, Hwang K. The toxicity of methotrexate in male fertility and paternal teratogenicity. Expert Opin Drug Metab Toxicol. 2017;13:51–8.

    Article  CAS  PubMed  Google Scholar 

  18. Grosen A, Kelsen J, Hvas CL, Bellaguarda E, Hanauer SB. The influence of methotrexate treatment on male fertility and pregnancy outcome after paternal exposure. Inflamm Bowel Dis. 2017;23:561–9.

    Article  PubMed  Google Scholar 

  19. Eluri S, Cross RK, Martin C, Weinfurt KP, Flynn KE, Long MD, et al. Inflammatory bowel diseases can adversely impact domains of sexual function such as satisfaction with sex life. Dig Dis Sci. 2018;63:1572–82.

    Article  PubMed  PubMed Central  Google Scholar 

  20. O’Toole A, de Silva PS, Marc LG, Ulysse CA, Testa MA, Ting A, et al. Sexual dysfunction in men with inflammatory bowel disease: a new IBD-specific scale. Inflamm Bowel Dis. 2018;24:310–6.

    Article  PubMed  PubMed Central  Google Scholar 

  21. de Lima A, Zelinkova Z, Mulders AGMGJ, van der Woude CJ. Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol. 2016;14:1285–1292.e1.

    Article  PubMed  Google Scholar 

  22. Martin J, Kane SV, Feagins LA. Fertility and contraception in women with inflammatory bowel disease. Gastroenterol Hepatol. 2016;12:101–9.

    Google Scholar 

  23. Williams JF, Smith VC, COMMITTEE ON SUBSTANCE ABUSE. Fetal alcohol spectrum disorders. Pediatrics. 2015;136:e1395–406.

    Article  PubMed  Google Scholar 

  24. Dolan-Mullen P, Ramírez G, Groff JY. A meta-analysis of randomized trials of prenatal smoking cessation interventions. Am J Obstet Gynecol. 1994;171:1328–34.

  25. Committee on Obstetric Practice. Committee opinion no. 722: marijuana use during pregnancy and lactation. Obstet Gynecol. 2017;130:e205–9.

    Article  Google Scholar 

  26. Santos MPC, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease. Ann Gastroenterol. 2018;31:14–23.

    PubMed  Google Scholar 

  27. Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011. Am J Gastroenterol. 2015;110:564–71.

    Article  PubMed  Google Scholar 

  28. Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology. Elsevier. 1991;100:1638–43.

  29. Aniwan S, Harmsen WS, Tremaine WJ, Loftus EV. Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010. Ther Adv Gastroenterol [Internet]. 2019 [cited 2020 Oct 17];12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376543/

  30. DeLisser M, Wei J, Ramalingam N, Velayos F, Hassid B. Variation in IBD prevalence by race/ethnicity within an integrated healthcare delivery system: 607. Off J Am Coll Gastroenterol ACG. 2018;113:S348.

    Article  Google Scholar 

  31. Nguyen GC, Chong CA, Chong RY. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohns Colitis. 2014;8:288–95.

    Article  PubMed  Google Scholar 

  32. Bengtson M-B, Martin CF, Aamodt G, Vatn MH, Mahadevan U. Inadequate gestational weight gain predicts adverse pregnancy outcomes in mothers with inflammatory bowel disease: results from a prospective US pregnancy cohort. Dig Dis Sci. 2017;62:2063–9.

    Article  PubMed  Google Scholar 

  33. Bischoff SC, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S, et al. ESPEN practical guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr. 2020;39:632–53.

    Article  PubMed  Google Scholar 

  34. Lee S, Metcalfe A, Raman M, Leung Y, Aghajafari F, Letourneau N, et al. Pregnant women with inflammatory bowel disease are at increased risk of vitamin D insufficiency: a cross-sectional study. J Crohns Colitis. 2018;12:702–9.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Pedersen N, Bortoli A, Duricova D, Inca RD, Panelli MR, Gisbert JP, et al. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther. 2013;38:501–12.

    Article  CAS  PubMed  Google Scholar 

  36. Yu A, Friedman S, Ananthakrishnan AN. Incidence and predictors of flares in the postpartum year among women with inflammatory bowel disease. Inflamm Bowel Dis [Internet]. [cited 2020 Oct 18]; Available from: https://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/izz313/5694104

  37. Pervez H, Usman N, Ahmed MM, Hashmi MS. The impact of inflammatory bowel disease on pregnancy and the fetus: a literature review. Cureus [Internet]. [cited 2020 18];11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822910/

  38. Hatch Q, Champagne BJ, Maykel JA, Davis BR, Johnson EK, Bleier JS, et al. Crohn’s disease and pregnancy: the impact of perianal disease on delivery methods and complications. Dis Colon Rectum. 2014;57:174–8.

    Article  PubMed  Google Scholar 

  39. Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology. Elsevier. 2017;152:451–462.e2.

  40. Shergill AK, Ben-Menachem T, Chandrasekhara V, Chathadi K, Decker GA, Evans JA, et al. Guidelines for endoscopy in pregnant and lactating women. Gastrointest Endosc. Elsevier. 2012;76:18–24.

  41. Food and Drug Administration, HHS. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist. 2014;79:72063–103.

    Google Scholar 

  42. •• Drugs and Lactation Database (LactMed). National Library of Medicine (US); 2006. Large database of drugs showing transfer of maternal-fetal drugs levels and its effects on breastfed infants.

  43. Gallinger ZR, Nguyen GC. Presence of phthalates in gastrointestinal medications: is there a hidden danger? World J Gastroenterol. 2013;19:7042–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Leung YPY, Kaplan GG, Coward S, Tanyingoh D, Kaplan BJ, Johnston DW, et al. Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease. J Crohns Colitis. 2015;9:223–30.

    Article  PubMed  Google Scholar 

  45. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65:240–61.

    Article  CAS  PubMed  Google Scholar 

  46. Bröms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014;20:1091–8.

    PubMed  Google Scholar 

  47. Casanova MJ, Chaparro M, Domènech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, et al. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:433–40.

    Article  CAS  PubMed  Google Scholar 

  48. •• Mahadevan U, Martin CF, Sandler RS, Kane SV, Dubinsky M, Lewis JD, et al. 865 PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012;142:S-149 Multicenter study of women with IBD during pregnancy and effects of various IBD treatments on maternal-fetal outcomes.

    Article  Google Scholar 

  49. Jharap B, de Boer NKH, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014;63:451–7.

    Article  CAS  PubMed  Google Scholar 

  50. Hyoun SC, Običan SG, Scialli AR. Teratogen update: methotrexate. Birt Defects Res A Clin Mol Teratol. 2012;94:187–207.

    Article  CAS  Google Scholar 

  51. Wu B, Tong J, Ran Z. Tacrolimus therapy in steroid-refractory ulcerative colitis: a review. Inflamm Bowel Dis. Oxford Academic. 2020;26:24–32.

  52. Paziana K, Del Monaco M, Cardonick E, Moritz M, Keller M, Smith B, et al. Ciclosporin use during pregnancy. Drug Saf. 2013;36:279–94.

    Article  CAS  PubMed  Google Scholar 

  53. Shannahan SE, Erlich JM, Peppercorn MA. Insights into the treatment of inflammatory bowel disease in pregnancy: Ther Adv Gastroenterol [Internet]. SAGE PublicationsSage UK: London, England; 2019 [cited 2020 Aug 20]; Available from: https://journals.sagepub.com/doi/10.1177/1756284819852231

  54. Baumgart DC, Sturm A, Wiedenmann B, Dignass AU. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut. 2005;54:1822–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Shibuya T, Haga K, Kamei M, Okahara K, Ito S, Takahashi M, et al. Successful remission of ulcerative colitis flare-up during pregnancy with adsorptive granulomonocytapheresis plus tacrolimus. Intest Res. Korean Association for the Study of Intestinal Diseases. 2018;16:484–8.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151:110–9.

    Article  CAS  PubMed  Google Scholar 

  57. • Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, et al. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: results from the Multicenter European TEDDY Study. Am J Gastroenterol. 2018;113:396–403 Large multicenter study demonstrating long-term safety of anti-TNFs in infants of treated pregnant women.

    Article  CAS  PubMed  Google Scholar 

  58. Seow CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, Tanyingoh D, Bindra G, et al. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1329–38.

    Article  CAS  PubMed  Google Scholar 

  59. Landi D Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS [Internet]. 2019 [cited 2020 Jul 31]. Available from: https://onlinelibrary.ectrims-congress.eu/ectrims/2019/stockholm/279583/doriana.landicontinuation.of.natalizumab.versus.interruption.is.associated.html

  60. Demortiere S. What is the best time to stop natalizumab in patients with active.... ECTRIMS Online Library. Demortière S. Sep 12 2019; 279141 [Internet]. [cited 2020 Jul 31]. Available from: https://onlinelibrary.ectrims-congress.eu/ectrims/2019/stockholm/279141/sarah.demortire.what.is.the.best.time.to.stop.natalizumab.in.patients.with.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D1603%2Aot_id%3D21674

  61. Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler Houndmills Basingstoke Engl. 2015;21:198–205.

    Article  CAS  Google Scholar 

  62. Chakraborti TK. Pharmacology Review(s) of Vedolizumab (Entyvio, MLN0002) [Internet]. 2013 [cited 2020 Oct 18]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125476Orig1s000PharmR.pdf.

  63. Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:941–50.

    Article  CAS  PubMed  Google Scholar 

  64. Moens A, van der Woude CJ, Julsgaard M, Humblet E, Sheridan J, Baumgart DC, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020;51:129–38.

    Article  CAS  PubMed  Google Scholar 

  65. Glassner K, Abraham BP. The use of vedolizumab in pregnancy and breastfeeding in women with inflammatory bowel disease. Inflamm Bowel Dis. 2019;5.

  66. Schaufelberg BW, Horn E, Rahawi K. Pregnancy outcomes in women exposed to ustekinumab in the psoriasis clinical development program. J Am Acad Dermatol. 2014;70:AB178.

    Article  Google Scholar 

  67. Puchner A, Gröchenig HP, Sautner J, Helmy-Bader Y, Juch H, Reinisch S, et al. Immunosuppressives and biologics during pregnancy and lactation. Wien Klin Wochenschr. 2019;131:29–44.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Martin PL, Sachs C, Imai N, Tsusaki H, Oneda S, Jiao Q, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89:351–63.

    Article  CAS  PubMed  Google Scholar 

  69. Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.

    Article  PubMed  Google Scholar 

  70. Pfizer Laboratories Div Pfizer Inc. XELJANZ- tofacitinib tablet (package insert) [Internet]. [cited 2020 May 24]. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=959

  71. Mahadevan U, Dubinsky MC, Su C, Lawendy N, Jones TV, Marren A, et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis Oxford Academic. 2018;24:2494–500.

  72. Pregnancy Team C for DE and Ciprofloxacin use by pregnant and lactating women. FDA [Internet]. FDA; 2018 [cited 2020 Oct 18]; Available from: https://www.fda.gov/drugs/bioterrorism-and-drug-preparedness/ciprofloxacin-use-pregnant-and-lactating-women

  73. Friedman JM, Polifka JE. Teratogenic effects of drugs: a resource for clinicians (TERIS). Baltimore: Johns Hopkins University Press; 2000.

    Google Scholar 

  74. Diav-Citrin O, Shechtman S, Gotteiner T, Arnon J, Ornoy A. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology. 2001;63:186–92.

    Article  CAS  PubMed  Google Scholar 

  75. Koss CA, Baras DC, Lane SD, Aubry R, Marcus M, Markowitz LE, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother. 2012;56:4800–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Sheehy O, Santos F, Ferreira E, Berard A. The use of metronidazole during pregnancy: a review of evidence. Curr Drug Saf. 2015;10:170–9.

    Article  CAS  PubMed  Google Scholar 

  77. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case-control teratologic study. Eur J Obstet Gynecol Reprod Biol. 2001;97:188–92.

    Article  CAS  PubMed  Google Scholar 

  78. Salix Pharmaceuticals, Inc. XIFAXAN- rifaximin tablet [Internet]. 2009 [cited 2020 Jul 19]. Available from: https://shared.salix.com/shared/pi/xifaxan550-pi.pdf

  79. Dozois EJ, Wolff BG, Tremaine WJ, Watson WJ, Drelichman ER, Carne PWG, et al. Maternal and fetal outcome after colectomy for fulminant ulcerative colitis during pregnancy: case series and literature review. Dis Colon Rectum. 2006;49:64–73.

    Article  PubMed  Google Scholar 

  80. Burke KE, Haviland MJ, Hacker MR, Shainker SA, Cheifetz AS. Indications for mode of delivery in pregnant women with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:721–6.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Foulon A, Dupas J-L, Sabbagh C, Chevreau J, Rebibo L, Brazier F, et al. Defining the most appropriate delivery mode in women with inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2017;23:712–20.

    Article  PubMed  Google Scholar 

  82. Ravid A, Richard CS, Spencer LM, O’Connor BI, Kennedy ED, MacRae HM, et al. Pregnancy, delivery, and pouch function after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2002;45:1283–8.

    Article  CAS  PubMed  Google Scholar 

  83. Remzi FH, Gorgun E, Bast J, Schroeder T, Hammel J, Philipson E, et al. Vaginal delivery after ileal pouch-anal anastomosis: a word of caution. Dis Colon Rectum. 2005;48:1691–9.

    Article  PubMed  Google Scholar 

  84. Nguyen GC, Bernstein CN, Bitton A, Chan AK, Griffiths AM, Leontiadis GI, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. Elsevier. 2014;146:835–848.e6.

    Article  PubMed  Google Scholar 

  85. Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41:92–128.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Breastfeeding SO. Breastfeeding and the use of human milk. Pediatrics:American Academy of Pediatrics. 2012;129:e827–41.

    Article  Google Scholar 

  87. CDC. Diet considerations for breastfeeding mothers. [Internet]. Cent. Dis. Control Prev. 2020 [cited 2020 Jul 25]. Available from: https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/diet-and-micronutrients/maternal-diet.html

  88. Juber BA, Jackson KH, Johnson KB, Harris WS, Baack ML. Breast milk DHA levels may increase after informing women: a community-based cohort study from South Dakota USA. Int Breastfeed J [Internet]. 2017 [cited 2020 Jul 25];12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5273852/

  89. Academy Of Breastfeeding Medicine Protocol Committee. ABM Clinical Protocol #9: Use of galactogogues in initiating or augmenting the rate of maternal milk secretion (First Revision January 2011). Breastfeed Med: Off J Acad Breastfeed Med. 2011;6:41–9.

    Article  Google Scholar 

  90. Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21:3365–9.

    Article  CAS  PubMed  Google Scholar 

  91. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104:228–33.

    Article  CAS  PubMed  Google Scholar 

  92. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2013;11:286–92 quiz e24.

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of Connecticut Health Care, 263 Farmington Avenue, Farmington, CT, 06030-8074, USA

    Sanket Patel DO & Haleh Vaziri MD

Authors
  1. Sanket Patel DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haleh Vaziri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haleh Vaziri MD.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Colon

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patel, S., Vaziri, H. Reproductive Health in IBD Patients. Curr Treat Options Gastro 19, 237–252 (2021). https://doi.org/10.1007/s11938-021-00334-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-021-00334-1

Keywords

Search

Navigation